Inclusion Criteria:
ALL SUBJECTS:
- Signed informed consent in the local language prior to any study-mandated procedure;
- Male/female aged 18 to 65 years (inclusive) at screening;
- Body mass index of 18.0 to 32.0 kg/m2 (inclusive) at screening. Body weight at least 50 kg;
- Women of childbearing potential must have a negative serum pregnancy test and use reliable birth controls up to 30 days after the end of study treatment.
HEALTHY SUBJECTS:
- Normal renal function confirmed by the estimated glomerular filtration rate (eGFR) determined at screening;
- Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.
SEVERE RENAL FUNCTION IMPAIRMENT SUBJECTS:
- Severe renal function impairment is defined by eGFR estimated at screening between 15 mL/min/1.73 m2 and 29 mL/min/1.73 m2 (inclusive).
Exclusion Criteria:
ALL SUBJECTS:
- Pregnant or lactating women;
- Known hypersensitivity to ACT-132577 or drugs of the same class, or any of their excipients;
- Known hypersensitivity or allergy to natural rubber latex;
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
SEVERE RENAL FUNCTION IMPAIRMENT SUBJECTS:
- End-stage renal disease that requires dialysis;
- Hemoglobin concentration < 9 g/dL;
- History of severe renal stenosis;
- Serum potassium concentration > 5.5 mmol/L;
- Presence of severe cardiac disease;
- History of clinically relevant bleeding disorder;
- Presence of any organ disorder, with the exception of renal function impairment, or use of any medication which might interfere with the pharmacokinetics of ACT-132577;
- Known life-threatening disease with a life expectancy of less than 1 year;
- Presence of unstable diabetes mellitus.